Beschikbare Ruimte

Labo's & kantoren van diverse afmetingen nu te huur.

 

Lees meer!

Happy Harriet Connect: meet Sightera & Cosprof

2025/02/20

On Thursday March, 20, 2025 @16h00 we invite you to join the Happy Harriet Connect: Meet Sightera & Cosprof: two new companies who moved into the Science Park. We are happy to introduce them to you! 

 

After a short presentation of each company (max 15 min), there will be time to ask questions. Following by some networking with the Science Park team and the companies of the park while enjoying some drinks and snacks.

 

The ideal way to get to know these two companies and the other businesses on the park ! Hope to see you all.

Register now

Some info on the companies:

- Cosprof: Where Science Meets Beauty. Cosprof is the leading innovation hub for R&D of cosmetic products, blending science with creativity to develop unique formulations that address market gaps while delivering the desired sensory and aesthetic experience. "We offer consulting and founder services, allowing small startups and established brands to flourish with the expertise of our in-house chemists and regulatory compliance specialists. Our mission is to transform the cosmetic industry by developing high-quality, transparent, and effective skincare products using ingredients of natural origin."

 

- Sightera Biosciences, a spin-off of the University of Antwerp and  Antwerp University Hospital (UZA), develops innovative small molecules within the field of oncology and regenerative medicine by combining patient-centered models with artificial intelligence. Sightera's goal is to significantly accelerate traditional drug development by incorporating an alternative and complementary technology to conventional small molecule discovery, namely SPAR technology. With our unique SPAR (Structure-Patient-Activity-Relationship) technology, we integrate chemical structures and patient-centered models to create more effective and relevant therapies at the start of the drug discovery process. Sightera aims to streamline traditional drug development by developing novel small molecules with high patient relevance within a short timeframe.